InvestorsHub Logo
Followers 1323
Posts 248094
Boards Moderated 62
Alias Born 12/07/2009

Re: Robertscott post# 2718

Tuesday, 07/11/2023 11:17:54 AM

Tuesday, July 11, 2023 11:17:54 AM

Post# of 2791
$NBIO Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets cell surface Vimentin (ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is a targeted immunotherapy that binds to the tumor via cell surface vimentin and recruits the host immune system to eliminate cancer cells.

About Nascent Biotech

Nascent Biotech, Inc. is a clinical-stage biotech company pioneering the development of human monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a human monoclonal Antibody (Mab) that is progressing to Phase 2 clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.
Bullish
Bullish

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NBIO News